KMTS · Kestra Medical Technologies

The thesis

Kestra Medical Technologies is modestly more likely than not to beat the S&P 500 over the next three months. Revenue from its ASSURE wearable defibrillator grew 60% in the fiscal first quarter, and gross margin reached 56.5%. The fiscal second-quarter report, which Kestra has not dated and which is estimated for about 10 December 2026, decides whether the $141 million fiscal 2027 revenue guide holds.

The shares closed at $31.63 on 11 November 2026, then at $28.62 on 12 November 2026. No new company results, guidance or filings accompanied the drop; the last results came on 14 September 2026. That report showed revenue of $31.0 million against $29 million expected, according to Investing.com. It raised the fiscal 2027 guide to $141 million from $137 million. The fiscal second quarter closed on 31 October 2026.

The market price already reflects continued growth. The $28.62 close sits just under MarketBeat's $29.00 average analyst target of 27 October 2026, and the three-month price change is 2.1%.

Insider selling is the main counterweight. The Form 4 filings from 22 October to 5 November 2026 show sales by a director, the chief financial officer and a chief business officer, covered in the Bear Case.

Bullish and bearish views on Kestra Medical Technologies, Ltd.

The bull case on Kestra Medical Technologies, Ltd. (KMTS), in brief: revenue and guidance rose together. The bear case: officers sold heavily in late October.

Bull case

• Revenue and guidance rose together. Kestra reported fiscal first-quarter revenue of $31.0 million on 14 September 2026, up 60% from a year earlier. It lifted the fiscal 2027 guide to $141 million from the $137 million issued in July. Fiscal 2026 revenue was $95.1 million, up 59%.
• Gross margin keeps widening. Fiscal first-quarter gross margin was 56.5% on 14 September 2026, against 45.7% a year earlier and 54.8% in the fiscal fourth quarter. Management credited volume, a higher in-network patient mix and cost improvements.
• Analyst targets sit above the price. MarketBeat's 27 October 2026 summary showed eight analysts, with five Buy, two Hold and one Sell ratings. Evercore ISI initiated with an Outperform rating and a $34 target on 20 October 2026, according to MarketBeat. BTIG's target is $32, reiterated on 15 September 2026 per Benzinga's ratings history.
• The shares hold above both moving averages. The $28.62 close on 12 November 2026 is above the 50-day average of $27.31 and the 200-day average of $24.06. The shares were still a record high on 11 November 2026, when the intraday high reached $31.99.

Bear case

• Officers sold heavily in late October. Form 4 filings show director Traci S. Umberger exercised options at $17.00 and sold 100,000 shares at an average of $27.18 on 21 October 2026, and 30,000 at $30.03 on 27 October 2026. Chief Financial Officer Vaseem Mahboob exercised and sold 79,500 shares at an average of $30.30 between 27 October 2026 and 29 October 2026. All three sales ran under Rule 10b5-1 pre-arranged trading plans.
• Other insiders sold as well. Director Brian Webster sold 15,000 shares at an average of $29.56 on 20 October 2026 under a pre-arranged plan. Chief Business Officer Timothy Moran sold 3,192 shares at $29.56 on 3 November 2026, a Form 4 filed 5 November 2026; Investing.com reported it covered tax withholding on vesting stock units.
• Losses are widening. The fiscal first-quarter net loss was $44.1 million against $25.8 million a year earlier, per Kestra's 14 September 2026 release. The $0.75 loss per share was wider than the $0.45 consensus Investing.com cited.
• Share gains are not measured directly. Kestra credits growth to market expansion, competitive share gains, new territories, patient mix and collection improvements. Its 14 September 2026 release gave no new ASSURE prescription count; the last was 6,357 for the quarter ended 30 April 2026.
• The price sits at the analyst average. The $28.62 close of 12 November 2026 is just under MarketBeat's $29.00 average target, so the December report has to lift estimates for targets to move higher.

Price setup

The shares closed at $28.62 on 12 November 2026. That is 10.5% below the 52-week intraday high of $31.99 set on 11 November 2026, when the close was $31.63. The 52-week closing low was $17.87 on 10 April 2026.

Recent closes were $28.53 on 5 November 2026, $28.80 on 6 November 2026, $30.12 on 9 November 2026 and $29.55 on 10 November 2026. The price has stayed between the high-$20s and the low $30s for the past week. The 3-month reference close was $28.02 on 14 August 2026.

The 50-day average is $27.31 and the 200-day average is $24.06, both as of the 12 November 2026 close. A close under the 50-day average would put the shares back inside the range that held in early November.

The estimated report date of about 10 December 2026 falls just outside the next 30 days. Kestra announced last year's second-quarter date on 3 December 2025 and reported on 11 December 2025.

Catalysts ahead

• 1 December 2026: Kestra presents at the Piper Sandler 38th Annual Healthcare Conference at 11:00 a.m. Eastern. It is the last scheduled public appearance before the estimated date of the fiscal second-quarter report and may add commentary on the $141 million guide.
• ~10 December 2026 (est.): Fiscal second-quarter 2027 earnings report; the company has not confirmed the date. It tests the $141 million fiscal 2027 revenue guide and whether the 56.5% gross margin persists while losses stay elevated.

What would change the view

A weekly close below $24.00, which would erase most of the recovery that followed the 14 September 2026 guidance raise. A cut to the $141 million fiscal 2027 revenue guide, or fiscal second-quarter revenue growth well below 60%, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• Revenue growth may reflect patient mix and collection improvements more than sustained share gains in wearable defibrillators. Confirmed by: the fiscal second-quarter release shows revenue growth well below 60% or a cut to the $141 million fiscal 2027 guide.
• Losses stay elevated as commercial expansion continues, despite the gross-margin gain. Confirmed by: the fiscal second-quarter net loss exceeds the year-earlier figure again while gross margin stops improving from 56.5%.
• Insider selling adds supply after the shares reached a record high on 11 November 2026. Confirmed by: new Form 4 filings show further officer or director sales, particularly outside pre-arranged Rule 10b5-1 plans.
• The fiscal 2027 guide depends on a second-half ramp from recently hired sales representatives. Confirmed by: management lowers second-half expectations or reports slower sales-representative productivity at the December report.
• The shares trade near MarketBeat's $29.00 average target, leaving less room if the December report disappoints. Confirmed by: analysts cut targets after the fiscal second-quarter report, or the 50-day average of $27.31 fails to hold on a weekly close.

What it trades with

Kestra has traded on company events: the guidance raise on 14 September 2026 and the insider filings of late October moved the shares more than any sector data. Kestra depends on one product line, so a reimbursement change or a competitive response in wearable defibrillators would hit it directly. As an unprofitable small-cap medical-device company, it also tends to move with appetite for small-cap growth shares when no company news is due.